nodes	percent_of_prediction	percent_of_DWPC	metapath
Halofantrine—CYP3A5—Irinotecan—colon cancer	0.21	0.283	CbGbCtD
Halofantrine—CYP2C8—Fluorouracil—colon cancer	0.194	0.262	CbGbCtD
Halofantrine—CYP3A5—Vincristine—colon cancer	0.184	0.248	CbGbCtD
Halofantrine—CYP3A4—Irinotecan—colon cancer	0.0819	0.111	CbGbCtD
Halofantrine—CYP3A4—Vincristine—colon cancer	0.0716	0.0966	CbGbCtD
Halofantrine—Hypertensive crisis—Capecitabine—colon cancer	0.0118	0.0454	CcSEcCtD
Halofantrine—Altered state of consciousness—Vincristine—colon cancer	0.0109	0.0419	CcSEcCtD
Halofantrine—Altered state of consciousness—Capecitabine—colon cancer	0.00709	0.0273	CcSEcCtD
Halofantrine—Haematocrit decreased—Methotrexate—colon cancer	0.00654	0.0252	CcSEcCtD
Halofantrine—Platelet count decreased—Capecitabine—colon cancer	0.0055	0.0212	CcSEcCtD
Halofantrine—Rigors—Capecitabine—colon cancer	0.00401	0.0155	CcSEcCtD
Halofantrine—Cerebrovascular accident—Irinotecan—colon cancer	0.00362	0.014	CcSEcCtD
Halofantrine—Orthostatic hypotension—Irinotecan—colon cancer	0.00324	0.0125	CcSEcCtD
Halofantrine—Depressed level of consciousness—Capecitabine—colon cancer	0.00316	0.0122	CcSEcCtD
Halofantrine—Abdominal distension—Irinotecan—colon cancer	0.00309	0.0119	CcSEcCtD
Halofantrine—Abnormal vision—Capecitabine—colon cancer	0.00285	0.011	CcSEcCtD
Halofantrine—Sleep disorder—Capecitabine—colon cancer	0.00274	0.0106	CcSEcCtD
Halofantrine—Stomatitis—Vincristine—colon cancer	0.00274	0.0106	CcSEcCtD
Halofantrine—Stomatitis—Irinotecan—colon cancer	0.00267	0.0103	CcSEcCtD
Halofantrine—Haemolytic anaemia—Capecitabine—colon cancer	0.00263	0.0101	CcSEcCtD
Halofantrine—Stomatitis—Fluorouracil—colon cancer	0.00255	0.00984	CcSEcCtD
Halofantrine—Cerebrovascular accident—Capecitabine—colon cancer	0.00242	0.00934	CcSEcCtD
Halofantrine—Visual impairment—Irinotecan—colon cancer	0.00237	0.00912	CcSEcCtD
Halofantrine—Depressed level of consciousness—Methotrexate—colon cancer	0.00235	0.00907	CcSEcCtD
Halofantrine—Face oedema—Capecitabine—colon cancer	0.00229	0.00884	CcSEcCtD
Halofantrine—Chills—Irinotecan—colon cancer	0.0022	0.00849	CcSEcCtD
Halofantrine—Arrhythmia—Irinotecan—colon cancer	0.00219	0.00846	CcSEcCtD
Halofantrine—Orthostatic hypotension—Capecitabine—colon cancer	0.00217	0.00836	CcSEcCtD
Halofantrine—Pulmonary oedema—Methotrexate—colon cancer	0.00217	0.00836	CcSEcCtD
Halofantrine—Back pain—Vincristine—colon cancer	0.00212	0.00818	CcSEcCtD
Halofantrine—Arrhythmia—Fluorouracil—colon cancer	0.0021	0.0081	CcSEcCtD
Halofantrine—Back pain—Irinotecan—colon cancer	0.00207	0.00797	CcSEcCtD
Halofantrine—Abdominal distension—Capecitabine—colon cancer	0.00207	0.00797	CcSEcCtD
Halofantrine—Ill-defined disorder—Irinotecan—colon cancer	0.00198	0.00764	CcSEcCtD
Halofantrine—Malaise—Irinotecan—colon cancer	0.00193	0.00743	CcSEcCtD
Halofantrine—Convulsion—Vincristine—colon cancer	0.0019	0.00733	CcSEcCtD
Halofantrine—Myalgia—Vincristine—colon cancer	0.00187	0.0072	CcSEcCtD
Halofantrine—Cough—Irinotecan—colon cancer	0.00187	0.00719	CcSEcCtD
Halofantrine—Cerebrovascular accident—Methotrexate—colon cancer	0.0018	0.00696	CcSEcCtD
Halofantrine—Discomfort—Irinotecan—colon cancer	0.0018	0.00693	CcSEcCtD
Halofantrine—Anaphylactic shock—Vincristine—colon cancer	0.00179	0.0069	CcSEcCtD
Halofantrine—Stomatitis—Capecitabine—colon cancer	0.00178	0.00688	CcSEcCtD
Halofantrine—Convulsion—Fluorouracil—colon cancer	0.00177	0.00684	CcSEcCtD
Halofantrine—Confusional state—Irinotecan—colon cancer	0.00176	0.00678	CcSEcCtD
Halofantrine—Anaphylactic shock—Irinotecan—colon cancer	0.00174	0.00672	CcSEcCtD
Halofantrine—Chest pain—Fluorouracil—colon cancer	0.00174	0.00672	CcSEcCtD
Halofantrine—Myalgia—Fluorouracil—colon cancer	0.00174	0.00672	CcSEcCtD
Halofantrine—Discomfort—Fluorouracil—colon cancer	0.00172	0.00664	CcSEcCtD
Halofantrine—Anorexia—Vincristine—colon cancer	0.00171	0.00658	CcSEcCtD
Halofantrine—Confusional state—Fluorouracil—colon cancer	0.00168	0.00649	CcSEcCtD
Halofantrine—Anaphylactic shock—Fluorouracil—colon cancer	0.00167	0.00644	CcSEcCtD
Halofantrine—Anorexia—Irinotecan—colon cancer	0.00166	0.00641	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Vincristine—colon cancer	0.00163	0.00629	CcSEcCtD
Halofantrine—Paraesthesia—Vincristine—colon cancer	0.00161	0.0062	CcSEcCtD
Halofantrine—Anorexia—Fluorouracil—colon cancer	0.00159	0.00614	CcSEcCtD
Halofantrine—Visual impairment—Capecitabine—colon cancer	0.00158	0.0061	CcSEcCtD
Halofantrine—Paraesthesia—Irinotecan—colon cancer	0.00157	0.00604	CcSEcCtD
Halofantrine—Decreased appetite—Vincristine—colon cancer	0.00156	0.006	CcSEcCtD
Halofantrine—Fatigue—Vincristine—colon cancer	0.00154	0.00595	CcSEcCtD
Halofantrine—Dyspepsia—Irinotecan—colon cancer	0.00154	0.00592	CcSEcCtD
Halofantrine—Tinnitus—Capecitabine—colon cancer	0.00153	0.00591	CcSEcCtD
Halofantrine—Constipation—Vincristine—colon cancer	0.00153	0.0059	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.00152	0.00587	CcSEcCtD
Halofantrine—Decreased appetite—Irinotecan—colon cancer	0.00152	0.00585	CcSEcCtD
Halofantrine—Fatigue—Irinotecan—colon cancer	0.0015	0.0058	CcSEcCtD
Halofantrine—Paraesthesia—Fluorouracil—colon cancer	0.0015	0.00578	CcSEcCtD
Halofantrine—Constipation—Irinotecan—colon cancer	0.00149	0.00575	CcSEcCtD
Halofantrine—Chills—Capecitabine—colon cancer	0.00147	0.00568	CcSEcCtD
Halofantrine—Dyspepsia—Fluorouracil—colon cancer	0.00147	0.00567	CcSEcCtD
Halofantrine—Arrhythmia—Capecitabine—colon cancer	0.00147	0.00566	CcSEcCtD
Halofantrine—Gastrointestinal pain—Vincristine—colon cancer	0.00146	0.00565	CcSEcCtD
Halofantrine—Decreased appetite—Fluorouracil—colon cancer	0.00145	0.0056	CcSEcCtD
Halofantrine—Feeling abnormal—Irinotecan—colon cancer	0.00144	0.00554	CcSEcCtD
Halofantrine—Gastrointestinal pain—Irinotecan—colon cancer	0.00143	0.0055	CcSEcCtD
Halofantrine—Abdominal pain—Vincristine—colon cancer	0.00142	0.00546	CcSEcCtD
Halofantrine—Back pain—Capecitabine—colon cancer	0.00138	0.00533	CcSEcCtD
Halofantrine—Abdominal pain—Irinotecan—colon cancer	0.00138	0.00532	CcSEcCtD
Halofantrine—Feeling abnormal—Fluorouracil—colon cancer	0.00138	0.00531	CcSEcCtD
Halofantrine—Stomatitis—Methotrexate—colon cancer	0.00133	0.00512	CcSEcCtD
Halofantrine—Ill-defined disorder—Capecitabine—colon cancer	0.00133	0.00512	CcSEcCtD
Halofantrine—Urticaria—Fluorouracil—colon cancer	0.00133	0.00512	CcSEcCtD
Halofantrine—Malaise—Capecitabine—colon cancer	0.00129	0.00497	CcSEcCtD
Halofantrine—Asthenia—Vincristine—colon cancer	0.00129	0.00495	CcSEcCtD
Halofantrine—Palpitations—Capecitabine—colon cancer	0.00126	0.00487	CcSEcCtD
Halofantrine—Asthenia—Irinotecan—colon cancer	0.00125	0.00482	CcSEcCtD
Halofantrine—Cough—Capecitabine—colon cancer	0.00125	0.00481	CcSEcCtD
Halofantrine—Diarrhoea—Vincristine—colon cancer	0.00123	0.00472	CcSEcCtD
Halofantrine—Arthralgia—Capecitabine—colon cancer	0.00122	0.00469	CcSEcCtD
Halofantrine—Chest pain—Capecitabine—colon cancer	0.00122	0.00469	CcSEcCtD
Halofantrine—Myalgia—Capecitabine—colon cancer	0.00122	0.00469	CcSEcCtD
Halofantrine—Discomfort—Capecitabine—colon cancer	0.0012	0.00464	CcSEcCtD
Halofantrine—Diarrhoea—Irinotecan—colon cancer	0.00119	0.0046	CcSEcCtD
Halofantrine—Dizziness—Vincristine—colon cancer	0.00118	0.00457	CcSEcCtD
Halofantrine—Pruritus—Fluorouracil—colon cancer	0.00118	0.00456	CcSEcCtD
Halofantrine—Visual impairment—Methotrexate—colon cancer	0.00118	0.00454	CcSEcCtD
Halofantrine—Confusional state—Capecitabine—colon cancer	0.00118	0.00454	CcSEcCtD
Halofantrine—Dizziness—Irinotecan—colon cancer	0.00115	0.00445	CcSEcCtD
Halofantrine—Diarrhoea—Fluorouracil—colon cancer	0.00114	0.00441	CcSEcCtD
Halofantrine—Tinnitus—Methotrexate—colon cancer	0.00114	0.0044	CcSEcCtD
Halofantrine—Vomiting—Vincristine—colon cancer	0.00114	0.00439	CcSEcCtD
Halofantrine—Rash—Vincristine—colon cancer	0.00113	0.00435	CcSEcCtD
Halofantrine—Dermatitis—Vincristine—colon cancer	0.00113	0.00435	CcSEcCtD
Halofantrine—Headache—Vincristine—colon cancer	0.00112	0.00433	CcSEcCtD
Halofantrine—Anorexia—Capecitabine—colon cancer	0.00111	0.00429	CcSEcCtD
Halofantrine—Vomiting—Irinotecan—colon cancer	0.00111	0.00428	CcSEcCtD
Halofantrine—Dizziness—Fluorouracil—colon cancer	0.0011	0.00426	CcSEcCtD
Halofantrine—Rash—Irinotecan—colon cancer	0.0011	0.00424	CcSEcCtD
Halofantrine—Dermatitis—Irinotecan—colon cancer	0.0011	0.00424	CcSEcCtD
Halofantrine—Chills—Methotrexate—colon cancer	0.0011	0.00423	CcSEcCtD
Halofantrine—Headache—Irinotecan—colon cancer	0.00109	0.00421	CcSEcCtD
Halofantrine—Nausea—Vincristine—colon cancer	0.00106	0.0041	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Capecitabine—colon cancer	0.00106	0.0041	CcSEcCtD
Halofantrine—Vomiting—Fluorouracil—colon cancer	0.00106	0.00409	CcSEcCtD
Halofantrine—Rash—Fluorouracil—colon cancer	0.00105	0.00406	CcSEcCtD
Halofantrine—Dermatitis—Fluorouracil—colon cancer	0.00105	0.00406	CcSEcCtD
Halofantrine—Paraesthesia—Capecitabine—colon cancer	0.00105	0.00404	CcSEcCtD
Halofantrine—Headache—Fluorouracil—colon cancer	0.00105	0.00403	CcSEcCtD
Halofantrine—Nausea—Irinotecan—colon cancer	0.00104	0.00399	CcSEcCtD
Halofantrine—Back pain—Methotrexate—colon cancer	0.00103	0.00397	CcSEcCtD
Halofantrine—Dyspepsia—Capecitabine—colon cancer	0.00103	0.00396	CcSEcCtD
Halofantrine—Decreased appetite—Capecitabine—colon cancer	0.00101	0.00391	CcSEcCtD
Halofantrine—Fatigue—Capecitabine—colon cancer	0.00101	0.00388	CcSEcCtD
Halofantrine—Constipation—Capecitabine—colon cancer	0.000998	0.00385	CcSEcCtD
Halofantrine—Nausea—Fluorouracil—colon cancer	0.000992	0.00383	CcSEcCtD
Halofantrine—Ill-defined disorder—Methotrexate—colon cancer	0.000988	0.00381	CcSEcCtD
Halofantrine—Feeling abnormal—Capecitabine—colon cancer	0.000962	0.00371	CcSEcCtD
Halofantrine—Malaise—Methotrexate—colon cancer	0.00096	0.0037	CcSEcCtD
Halofantrine—Gastrointestinal pain—Capecitabine—colon cancer	0.000955	0.00368	CcSEcCtD
Halofantrine—Cough—Methotrexate—colon cancer	0.000929	0.00358	CcSEcCtD
Halofantrine—Urticaria—Capecitabine—colon cancer	0.000928	0.00358	CcSEcCtD
Halofantrine—Abdominal pain—Capecitabine—colon cancer	0.000923	0.00356	CcSEcCtD
Halofantrine—Convulsion—Methotrexate—colon cancer	0.000923	0.00356	CcSEcCtD
Halofantrine—Arthralgia—Methotrexate—colon cancer	0.000907	0.00349	CcSEcCtD
Halofantrine—Chest pain—Methotrexate—colon cancer	0.000907	0.00349	CcSEcCtD
Halofantrine—Myalgia—Methotrexate—colon cancer	0.000907	0.00349	CcSEcCtD
Halofantrine—Discomfort—Methotrexate—colon cancer	0.000896	0.00345	CcSEcCtD
Halofantrine—Confusional state—Methotrexate—colon cancer	0.000876	0.00338	CcSEcCtD
Halofantrine—Anaphylactic shock—Methotrexate—colon cancer	0.000869	0.00335	CcSEcCtD
Halofantrine—Asthenia—Capecitabine—colon cancer	0.000838	0.00323	CcSEcCtD
Halofantrine—Anorexia—Methotrexate—colon cancer	0.000829	0.00319	CcSEcCtD
Halofantrine—Pruritus—Capecitabine—colon cancer	0.000826	0.00318	CcSEcCtD
Halofantrine—Diarrhoea—Capecitabine—colon cancer	0.000799	0.00308	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000792	0.00305	CcSEcCtD
Halofantrine—Paraesthesia—Methotrexate—colon cancer	0.00078	0.00301	CcSEcCtD
Halofantrine—Dizziness—Capecitabine—colon cancer	0.000772	0.00298	CcSEcCtD
Halofantrine—Dyspepsia—Methotrexate—colon cancer	0.000765	0.00295	CcSEcCtD
Halofantrine—Decreased appetite—Methotrexate—colon cancer	0.000756	0.00291	CcSEcCtD
Halofantrine—Fatigue—Methotrexate—colon cancer	0.000749	0.00289	CcSEcCtD
Halofantrine—Vomiting—Capecitabine—colon cancer	0.000742	0.00286	CcSEcCtD
Halofantrine—Rash—Capecitabine—colon cancer	0.000736	0.00284	CcSEcCtD
Halofantrine—Dermatitis—Capecitabine—colon cancer	0.000736	0.00284	CcSEcCtD
Halofantrine—Headache—Capecitabine—colon cancer	0.000731	0.00282	CcSEcCtD
Halofantrine—Feeling abnormal—Methotrexate—colon cancer	0.000716	0.00276	CcSEcCtD
Halofantrine—Gastrointestinal pain—Methotrexate—colon cancer	0.000711	0.00274	CcSEcCtD
Halofantrine—Nausea—Capecitabine—colon cancer	0.000694	0.00267	CcSEcCtD
Halofantrine—Urticaria—Methotrexate—colon cancer	0.00069	0.00266	CcSEcCtD
Halofantrine—Abdominal pain—Methotrexate—colon cancer	0.000687	0.00265	CcSEcCtD
Halofantrine—Asthenia—Methotrexate—colon cancer	0.000624	0.0024	CcSEcCtD
Halofantrine—Pruritus—Methotrexate—colon cancer	0.000615	0.00237	CcSEcCtD
Halofantrine—Diarrhoea—Methotrexate—colon cancer	0.000595	0.00229	CcSEcCtD
Halofantrine—Dizziness—Methotrexate—colon cancer	0.000575	0.00222	CcSEcCtD
Halofantrine—Vomiting—Methotrexate—colon cancer	0.000553	0.00213	CcSEcCtD
Halofantrine—Rash—Methotrexate—colon cancer	0.000548	0.00211	CcSEcCtD
Halofantrine—Dermatitis—Methotrexate—colon cancer	0.000548	0.00211	CcSEcCtD
Halofantrine—Headache—Methotrexate—colon cancer	0.000545	0.0021	CcSEcCtD
Halofantrine—Nausea—Methotrexate—colon cancer	0.000516	0.00199	CcSEcCtD
